SEC Form 4 · accession 0001209191-17-059632
Dimension Therapeutics, Inc. · DMTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mary Thistle
Officer — Chief Operating Officer
Period of report
Nov 7, 2017
Accepted (ET)
Nov 7, 2017 · 5:11 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001592288
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $3.57 | Nov 7, 2017 | D | 27,711 | D | — | Apr 28, 2025 | Common Stock | 27,711 | 0 | D |
| Stock Option (Right to Buy)F2 | $3.57 | Nov 7, 2017 | D | 180,815 | D | — | Apr 28, 2025 | Common Stock | 180,815 | 0 | D |
| Stock Option (Right to Buy)F3 | $4.09 | Nov 7, 2017 | D | 17,104 | D | — | Jun 2, 2025 | Common Stock | 17,104 | 0 | D |
| Stock Option (Right to Buy)F4 | $7.14 | Nov 7, 2017 | D | 65,000 | D | — | Jan 31, 2026 | Common Stock | 65,000 | 0 | D |
| Stock Option (Right to Buy)F5 | $1.90 | Nov 7, 2017 | D | 60,000 | D | — | Jan 31, 2027 | Common Stock | 60,000 | 0 | D |
Explanation of responses
- F1This stock option, which vests over four years beginning February 2, 2015, at a rate of 25% after 12 months, and in 36 equal monthly installments thereafter, was assumed by Ultragenyx Pharmaceutical Inc. ("Ultragenyx"), and converted in accordance with the exchange ratio as set forth in the Agreement and Plan of Merger (the "Merger Agreement"), dated October 2, 2017, between the Issuer, Ultragenyx and Mystic River Merger Sub Inc., a direct, wholly-owned subsidiary of Ultragenyx.
- F2This stock option, which vests over four years beginning February 2, 2015, at a rate of 25% after 12 months, and in 36 equal monthly installments thereafter, was assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement.
- F3This stock option, which vested 2,494 shares on February 2, 2016, and vests in 41 equal monthly installments thereafter, beginning February 3, 2016, was assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement.
- F4This stock option, which vests in 48 equal monthly installments beginning January 27, 2016, was assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement.
- F5This stock option, which vests in 48 equal monthly installments beginning January 18, 2017, was assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement.